Regenxbio (NASDAQ:RGNX) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Monday.
A number of other research firms have also recently commented on RGNX. Raymond James set a $96.00 price objective on Regenxbio and gave the stock a “buy” rating in a research report on Thursday, November 8th. BidaskClub upgraded Regenxbio from a “hold” rating to a “buy” rating in a research report on Saturday, November 3rd. Zacks Investment Research upgraded Regenxbio from a “hold” rating to a “buy” rating and set a $78.00 price target for the company in a report on Wednesday, November 7th. Bank of America lifted their price target on Regenxbio from $76.00 to $84.00 and gave the company a “neutral” rating in a report on Thursday, November 8th. Finally, Leerink Swann began coverage on Regenxbio in a report on Tuesday, November 27th. They issued an “underperform” rating and a $42.00 price target for the company. Two analysts have rated the stock with a sell rating, two have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $74.81.
Regenxbio stock opened at $47.12 on Monday. The stock has a market cap of $1.60 billion, a P/E ratio of -19.23 and a beta of 0.41. Regenxbio has a 52 week low of $23.25 and a 52 week high of $85.10.
Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.30. The firm had revenue of $5.31 million during the quarter. Regenxbio had a return on equity of 22.52% and a net margin of 44.30%. As a group, analysts expect that Regenxbio will post 2.34 earnings per share for the current year.
In other Regenxbio news, insider Kenneth T. Mills sold 15,000 shares of Regenxbio stock in a transaction dated Tuesday, January 15th. The stock was sold at an average price of $43.85, for a total value of $657,750.00. Following the completion of the sale, the insider now owns 204,140 shares in the company, valued at approximately $8,951,539. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Vittal Vasista sold 7,500 shares of Regenxbio stock in a transaction dated Thursday, November 15th. The shares were sold at an average price of $60.29, for a total value of $452,175.00. The disclosure for this sale can be found here. Insiders sold a total of 224,879 shares of company stock valued at $13,351,900 in the last 90 days. 16.90% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Riverhead Capital Management LLC lifted its stake in shares of Regenxbio by 137.5% in the 3rd quarter. Riverhead Capital Management LLC now owns 1,900 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 1,100 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Regenxbio in the 2nd quarter valued at about $157,000. LS Investment Advisors LLC lifted its stake in shares of Regenxbio by 63.1% in the 4th quarter. LS Investment Advisors LLC now owns 2,260 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 874 shares in the last quarter. Harvest Fund Management Co. Ltd acquired a new position in shares of Regenxbio in the 3rd quarter valued at about $190,000. Finally, Meeder Asset Management Inc. lifted its stake in shares of Regenxbio by 31.7% in the 4th quarter. Meeder Asset Management Inc. now owns 2,578 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 621 shares in the last quarter. 79.14% of the stock is currently owned by institutional investors and hedge funds.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Featured Story: Options Trading – What is a Straddle?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.